Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.075 USD | +5.39% | +5.94% | -22.46% |
May. 09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.46% | 197M | |
+4.88% | 111B | |
+12.26% | 105B | |
-12.76% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.81% | 16.96B | |
+4.47% | 13.7B | |
+36.75% | 12.45B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Wedbush Adjusts bluebird bio Price Target to $7 From $5, Maintains Neutral Rating